Copyright Reports & Markets. All rights reserved.

Global Live Attenuated Japanese Encephalitis Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 0.5ml
    • 1.3.3 1ml
    • 1.3.4 2.5ml
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
  • 1.5 Global Live Attenuated Japanese Encephalitis Vaccine Market Size & Forecast
    • 1.5.1 Global Live Attenuated Japanese Encephalitis Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novartis
    • 2.1.1 Novartis Details
    • 2.1.2 Novartis Major Business
    • 2.1.3 Novartis Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.1.4 Novartis Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novartis Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.2.4 Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 Chengdu Institute of Biological Products
    • 2.3.1 Chengdu Institute of Biological Products Details
    • 2.3.2 Chengdu Institute of Biological Products Major Business
    • 2.3.3 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.3.4 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Chengdu Institute of Biological Products Recent Developments/Updates
  • 2.4 Wuhan Institute of Biological Products
    • 2.4.1 Wuhan Institute of Biological Products Details
    • 2.4.2 Wuhan Institute of Biological Products Major Business
    • 2.4.3 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.4.4 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Wuhan Institute of Biological Products Recent Developments/Updates
  • 2.5 Lanzhou Institute of Biological Products
    • 2.5.1 Lanzhou Institute of Biological Products Details
    • 2.5.2 Lanzhou Institute of Biological Products Major Business
    • 2.5.3 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.5.4 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Lanzhou Institute of Biological Products Recent Developments/Updates
  • 2.6 Beijing Temple of Heaven Biological Products
    • 2.6.1 Beijing Temple of Heaven Biological Products Details
    • 2.6.2 Beijing Temple of Heaven Biological Products Major Business
    • 2.6.3 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.6.4 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Beijing Temple of Heaven Biological Products Recent Developments/Updates
  • 2.7 Valneva
    • 2.7.1 Valneva Details
    • 2.7.2 Valneva Major Business
    • 2.7.3 Valneva Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.7.4 Valneva Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Valneva Recent Developments/Updates
  • 2.8 Bharat Biotech
    • 2.8.1 Bharat Biotech Details
    • 2.8.2 Bharat Biotech Major Business
    • 2.8.3 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.8.4 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Bharat Biotech Recent Developments/Updates
  • 2.9 Cheng Da Biology
    • 2.9.1 Cheng Da Biology Details
    • 2.9.2 Cheng Da Biology Major Business
    • 2.9.3 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.9.4 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Cheng Da Biology Recent Developments/Updates
  • 2.10 Biocelect Pty Ltd
    • 2.10.1 Biocelect Pty Ltd Details
    • 2.10.2 Biocelect Pty Ltd Major Business
    • 2.10.3 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.10.4 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Biocelect Pty Ltd Recent Developments/Updates
  • 2.11 Glovax Co., Ltd.
    • 2.11.1 Glovax Co., Ltd. Details
    • 2.11.2 Glovax Co., Ltd. Major Business
    • 2.11.3 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product and Services
    • 2.11.4 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Glovax Co., Ltd. Recent Developments/Updates

3 Competitive Environment: Live Attenuated Japanese Encephalitis Vaccine by Manufacturer

  • 3.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Live Attenuated Japanese Encephalitis Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Live Attenuated Japanese Encephalitis Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Live Attenuated Japanese Encephalitis Vaccine Manufacturer Market Share in 2025
  • 3.5 Live Attenuated Japanese Encephalitis Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Live Attenuated Japanese Encephalitis Vaccine Market: Region Footprint
    • 3.5.2 Live Attenuated Japanese Encephalitis Vaccine Market: Company Product Type Footprint
    • 3.5.3 Live Attenuated Japanese Encephalitis Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Live Attenuated Japanese Encephalitis Vaccine Market Size by Region
    • 4.1.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Live Attenuated Japanese Encephalitis Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Live Attenuated Japanese Encephalitis Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Consumption Value (2021-2032)
  • 4.5 South America Live Attenuated Japanese Encephalitis Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Live Attenuated Japanese Encephalitis Vaccine Market Size by Country
    • 7.3.1 North America Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Live Attenuated Japanese Encephalitis Vaccine Market Size by Country
    • 8.3.1 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Live Attenuated Japanese Encephalitis Vaccine Market Size by Country
    • 10.3.1 South America Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Live Attenuated Japanese Encephalitis Vaccine Market Drivers
  • 12.2 Live Attenuated Japanese Encephalitis Vaccine Market Restraints
  • 12.3 Live Attenuated Japanese Encephalitis Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Live Attenuated Japanese Encephalitis Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Live Attenuated Japanese Encephalitis Vaccine
  • 13.3 Live Attenuated Japanese Encephalitis Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Live Attenuated Japanese Encephalitis Vaccine Typical Distributors
  • 14.3 Live Attenuated Japanese Encephalitis Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Live Attenuated Japanese Encephalitis Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Epidemic Japanese encephalitis (hereinafter referred to as "JE") is an acute infectious disease of the central nervous system caused by the Japanese encephalitis virus, with inflammation of the brain parenchyma as the main lesion.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Live Attenuated Japanese Encephalitis Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Live Attenuated Japanese Encephalitis Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Live Attenuated Japanese Encephalitis Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Live Attenuated Japanese Encephalitis Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Live Attenuated Japanese Encephalitis Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Live Attenuated Japanese Encephalitis Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Live Attenuated Japanese Encephalitis Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Sanofi, Chengdu Institute of Biological Products, Wuhan Institute of Biological Products, Lanzhou Institute of Biological Products, Beijing Temple of Heaven Biological Products, Valneva, Bharat Biotech, Cheng Da Biology, Biocelect Pty Ltd, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Live Attenuated Japanese Encephalitis Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    0.5ml
    1ml
    2.5ml
    Market segment by Application
    Hospital
    Clinic
    Major players covered
    Novartis
    Sanofi
    Chengdu Institute of Biological Products
    Wuhan Institute of Biological Products
    Lanzhou Institute of Biological Products
    Beijing Temple of Heaven Biological Products
    Valneva
    Bharat Biotech
    Cheng Da Biology
    Biocelect Pty Ltd
    Glovax Co., Ltd.
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Live Attenuated Japanese Encephalitis Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Live Attenuated Japanese Encephalitis Vaccine, with price, sales quantity, revenue, and global market share of Live Attenuated Japanese Encephalitis Vaccine from 2021 to 2026.
    Chapter 3, the Live Attenuated Japanese Encephalitis Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Live Attenuated Japanese Encephalitis Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Live Attenuated Japanese Encephalitis Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Live Attenuated Japanese Encephalitis Vaccine.
    Chapter 14 and 15, to describe Live Attenuated Japanese Encephalitis Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now